Trevi Therapeutics Q1 net loss $10.3M; positive RIVER trial results; CORAL data expected Q2 2025

Trevi Therapeutics, Inc.

2025-Q1 EPS reported -$0.09

Net loss of $10.3M ($10.9M YoY); R&D expenses $7.8M, G&A $3.7M.
RIVER Phase 2a positive: 67% cough reduction from baseline, 57% placebo-adjusted (p<0.0001).
CORAL Phase 2b enrollment completed Feb 2025; last patient visit Apr 2025; topline results on track for Q2 2025.
Cash, equivalents and marketable securities $103.3M; runway expected into Q4 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.